SVB Securities analyst Thomas Smith raised the firm’s price target on Morphic to $56 from $45 driven by incrementally higher probability-of-success assumptions for lead product candidate MORF-057 in both ulcerative colitis and Crohn’s disease. The firm keeps an Outperform rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MORF: